Loss of NF1 function, a well-known tumour-suppressor gene in melanoma, has been implicated on multiple occasions in resistance to PLX4032 targeted therapies [18-21] in BRAF-mutant melanoma. The gene discussed is BRAF; the disease is melanoma.